The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy

NeuroImage: Clinical

Norbert Galldiks¹  Javier Arbizu²  Whitney B. Pope³  Ian Law⁴  Karl-Josef Langen⁵ 

[1] Dept. of Neurology, University of Cologne, Cologne, Germany;Dept. of Nuclear Medicine, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain;Dept. of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States;Dept.of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark;Institute of Neuroscience and Medicine, Forschungszentrum Jülich, Jülich, Germany;

关键词: PET;    FET;    MET;    FDOPA;    Glioma;    Temozolomide;    Bevacizumab;    Immunotherapy;    Checkpoint inhibitors;    Pseudoprogression;    Pseudoresponse;   

DOI  :  10.1016/j.nicl.2016.12.020

来源: DOAJ

【 摘 要 】

Routine diagnostics and treatment monitoring of brain tumors is usually based on contrast-enhanced MRI. However, the capacity of conventional MRI to differentiate tumor tissue from posttherapeutic effects following neurosurgical resection, chemoradiation, alkylating chemotherapy, radiosurgery, and/or immunotherapy may be limited. Metabolic imaging using PET can provide relevant additional information on tumor metabolism, which allows for more accurate diagnostics especially in clinically equivocal situations. This review article focuses predominantly on the amino acid PET tracers 11C-methyl-l-methionine (MET), O-(2-[18F]fluoroethyl)-l-tyrosine (FET) and 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine (FDOPA) and summarizes investigations regarding monitoring of brain tumor therapy.

【 授权许可】

Unknown